Rallybio Corp (RLYB) USD0.0001

Sell:$0.41Buy:$0.41$0.01 (2.58%)

NASDAQ:0.22%
Market closed | Prices delayed by at least 15 minutes
Sell:$0.41
Buy:$0.41
Change:$0.01 (2.58%)
Market closed | Prices delayed by at least 15 minutes
Sell:$0.41
Buy:$0.41
Change:$0.01 (2.58%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Key people

Stephen Uden
President, Chief Executive Officer, Director
Jonathan I. Lieber
Chief Financial Officer, Treasurer
Steven W. Ryder
Chief Medical Officer
Helen M. Boudreau
Independent Director
Wendy K. Chung
Independent Director
Robert Hopfner
Independent Director
Ronald M. Hunt
Independent Director
Lucian Iancovici
Independent Director
Click to see more

Key facts

  • EPIC
    RLYB
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US75120L1008
  • Market cap
    $18.58m
  • Employees
    24
  • Shares in issue
    41.61m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.